PROGRAMME of INDUSTRY SYMPOSIA

on the occasion of the 51st Annual Meeting
of the European Association for the Study of Diabetes

EASD STOCKHOLM
14 September 2015
17 September 2015

www.easd-industry.com
Individualised patient care in Type 2 diabetes: Translating science to practice

Symposium on the occasion of the 51st Annual Meeting of the European Association for the Study of Diabetes

Monday 14 September 2015, 10:30–16:30
Heding Hall, Stockholmsmässan

Making the right choice at the right time with our patients is key to ensuring their future wellbeing. But with the vast array of potential therapies now available, and the science behind diabetes management advancing rapidly, how can we ensure we are pursuing the optimal treatment approach with each individual?

In this symposium we will translate the science and bring our patients into focus through interactive talks, interviews, discussions and Q&A sessions with world-leading experts.

Join us to explore key questions in patient management, and share views and clinical experience with the aim of raising the standard of care for patients living with diabetes.

Join us and be part of the debate!

Professor Chantal Mathieu
University of Leuven, Leuven, Belgium (Co-chair)

Professor Jiten Vora
Head of External Scientific Affairs, AstraZeneca, and Professor of Endocrinology, University of Liverpool, Liverpool, UK (Co-chair)

AstraZeneca
What science can do

Organised and funded by AstraZeneca

10:30–11:00
Welcome and introduction: why and when should we treat Type 2 diabetes?
C Mathieu (Belgium), J Vora (UK)

11:00–11:30
Treatment decisions for our patients: what are the considerations?
R Pratley (US)

11:30–11:55
Weight gain in the treatment of Type 2 diabetes: is it inevitable?
J Wilding (UK)

11:55–12:20
The kidneys in Type 2 diabetes: challenges and opportunities?
M Cooper (Australia)

12:20–12:45
Can we delay escalation to insulin therapy?
T Vilsbøll (Denmark)

12:45–13:00
What steps should we take to stop progression of poor glucose control?
Panel discussion led by C Mathieu (Belgium), J Vora (UK)

13:00–14:00
Lunch

14:00–14:10
Welcome back
C Mathieu (Belgium), J Vora (UK)

14:10–14:40
Safety of novel therapies in Type 2 diabetes: what’s the latest?
J Meier (Germany)

14:40–15:05
What is the physiological basis for combining therapies?
J Holst (Denmark)

15:05–15:35
Why not combine earlier?
J Seufert (Germany)

15:35–16:00
What can we expect for future management of diabetes?
M Davies (UK)

16:00–16:25
How should we make the right treatment choices for our patients?
Panel discussion led by C Mathieu (Belgium), J Vora (UK)

16:25–16:30
Wrap up and close
C Mathieu (Belgium), J Vora (UK)
Dear Guests,

It will be a great honour and pleasure to welcome you to the 51st EASD Annual Meeting from 14 – 18 September 2015 in Stockholm, Sweden.

For many years, an integral part of the EASD Congress has been the symposia on the occasion of our Annual Meeting which have provided state-of-the-art information on developments in diabetes care and research. These symposia offer a range of valuable information and knowledge on clinical and basic research in the field of diabetes, new and upcoming treatments and major developments in the field of diabetes and its complications.

They attract opinion leaders, academic researchers, physicians and other health care professionals and offer an excellent platform for discussion and the opportunity to learn about new research as well as the latest news and updates in the world of diabetes research and care.

Beginning on September 14 with the industry symposia, an international audience of academics, researchers and physicians from over 100 countries will descend on the Stockholmsmässan in Stockholm.

For the first time in the history of the EASD Congress, I have the pleasure to invite you to attend the industry mini symposia, which take place in the afternoon of 14 September, and the industry evening symposia, which take place directly after the EASD Scientific Programme on 17 September.

These sessions provide an outstanding forum for interaction, communication, education and collaboration and are an excellent introduction to the official EASD Scientific Programme which will begin on September 15.

On behalf of EASD and the Local Organising committee, I encourage you to actively take part in the symposia on the occasion of the Annual Meeting of the European Association for the Study of Diabetes during what promises to be an outstanding 51st EASD Annual Meeting.

I look forward to welcoming you to Stockholm.

Prof. Andrew J.M. Boulton
President, EASD
CONTENT

SCHEDULE ................................................................................................................................ 5
HALL OVERVIEW ...................................................................................................................................... 6
PROGRAMME OF INDUSTRY SYMPOSIA ................................................................................................. 7

Sanofi Diabetes
Different patients, different needs: towards an integrated care approach in diabetes care ........................................8

Novo Nordisk
Evolving perspectives in treating diabetes and obesity .................................................................................. 10

AstraZeneca
Individualised patient care in Type 2 diabetes: translating science to practice ............................................. 12

Boehringer Ingelheim & Eli Lilly and Company
Getting to the heart of Type 2 Diabetes ........................................................................................................ 13

Novartis Pharmaceuticals
The future of diabetes: opportunities and challenges ..................................................................................... 14

DexCom
Dexcom Continuous Glucose Monitoring in 2015 – Clinical Practice, Technology Innovations and Market Access ...... 16

Pfizer
Translational Pursuits ................................................................................................................................ 17

Zydus Cadila
SAROGLITAZAR – A breakthrough discovery in the management of metabolic disorders .................................. 18

Merck Sharp & Dohme
Lessons Learned from the TECOS CV Safety Trial and the Evolving Role of DPP-4 Inhibitors in the Treatment of Patients with Type 2 Diabetes ................................................................. 19

Amgen
Diabetic dyslipidemia, cardiovascular disease and PCSK9 inhibition with evolocumab: 4 key questions ........... 20

Becton Dickinson & Company Inc.
Optimizing Insulin Pump Therapy: Infusion Set Failures and Silent Occlusions ............................................. 22

Takeda
Should type 2 diabetes (T2D) management be more of a priority in post-acute coronary syndrome (ACS) patients? .... 24

Roche Diabetes Care
How much can technology support Personalized Diabetes Management .......................................................... 26

Medscape Education supported by an independent educational grant from Janssen
Should SGLT2 Inhibitors Be An Integral Part of a Personalized Treatment Plan for Type 2 Diabetes? ............. 28

Abbott
One year with flash glucose monitoring – Perspectives from different stakeholders in diabetes care. What’s next? ...... 29

PROGRAMME OF INDUSTRY MINI SYMPOSIA .................................................................................. 30

LG Life Sciences
What is the Optimized treatment for T2DM patients? ..................................................................................... 30

Aegerion
The Metabolic Chaos of Lipodystrophy – Finding the Order Within ................................................................ 32

Eli Lilly and Company
Challenges in Comprehensive Lipid Management ........................................................................................... 33

PROGRAMME OF INDUSTRY EVENING SYMPOSIA ......................................................................... 35

Novo Nordisk
GLP-1 receptor agonists: liraglutide 3.0 mg in weight management ................................................................. 35

Boehringer Ingelheim & Eli Lilly and Company
EMPA-REG OUTCOME®: Implications for management of patients with Type 2 Diabetes .............................. 36

Merck Sharp & Dohme
The TECOS CV Safety Trial and the Lessons Learned for Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease ................................................................................................... 38

Eli Lilly and Company
The Patient in Mind: new perspectives on injectable therapy for type 2 diabetes ............................................ 39

BADGES DURING SYMPOSIA DAYS ................................................................................................... 41

IMPRINT .................................................................................................................................................. 42
### Monday, 14 September 2015

#### Industry Symposia

<table>
<thead>
<tr>
<th>Time</th>
<th>09:00</th>
<th>10:00</th>
<th>11:00</th>
<th>12:00</th>
<th>13:00</th>
<th>14:00</th>
<th>15:00</th>
<th>16:00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keen Hall</td>
<td>Keen Hall</td>
<td>Sanofi Diabetes</td>
<td>Page 8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hellerström Hall</td>
<td>Hellerström Hall</td>
<td>Novo Nordisk</td>
<td>Page 10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heding Hall</td>
<td>Heding Hall</td>
<td>AstraZeneca</td>
<td>Page 12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peltonen-Palotie Hall</td>
<td>Peltonen-Palotie Hall</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jacobsohn Hall</td>
<td>Jacobsohn Hall</td>
<td>Novartis</td>
<td>Page 14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meyer-Schwickerath Hall</td>
<td>Meyer-Schwickerath Hall</td>
<td>DexCom</td>
<td>Page 16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rahbar Hall A</td>
<td>Rahbar Hall A</td>
<td>Zydus Cadila</td>
<td>Page 18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doniach Hall</td>
<td>Doniach Hall</td>
<td>Merck Sharp &amp; Dohme</td>
<td>Page 19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rahbar Hall B</td>
<td>Rahbar Hall B</td>
<td>Pfizer</td>
<td>Page 17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kimmelstiel Hall</td>
<td>Kimmelstiel Hall</td>
<td>Takeda</td>
<td>Page 24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bouchardat Hall</td>
<td>Bouchardat Hall</td>
<td>Roche Diabetes Care</td>
<td>Page 26</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loubatière Hall</td>
<td>Loubatière Hall</td>
<td>Medscape Education</td>
<td>Page 28</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sterne Hall</td>
<td>Sterne Hall</td>
<td>Abbott</td>
<td>Page 29</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Industry Mini Symposia

<table>
<thead>
<tr>
<th>Time</th>
<th>17:00 – 18:00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schmidt Hall</td>
<td>LG Life Sciences</td>
</tr>
<tr>
<td>Hodgkin Hall</td>
<td>Aegerion</td>
</tr>
<tr>
<td>Pirart Hall</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Sanger Hall</td>
<td>AstraZeneca</td>
</tr>
</tbody>
</table>

### Thursday, 17 September 2015

#### Industry Evening Symposia

<table>
<thead>
<tr>
<th>Time</th>
<th>19:00</th>
<th>20:00</th>
<th>21:00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loubatière Hall</td>
<td>Loubatière Hall</td>
<td>Novo Nordisk</td>
<td>Page 35</td>
</tr>
<tr>
<td>Meyer-Schwickerath Hall</td>
<td>Meyer-Schwickerath Hall</td>
<td>Boehringer Ingelheim &amp; Eli Lilly and Company</td>
<td>Page 36</td>
</tr>
<tr>
<td>Kimmelstiel Hall</td>
<td>Kimmelstiel Hall</td>
<td>Merck Sharp &amp; Dohme</td>
<td>Page 38</td>
</tr>
<tr>
<td>Elite Hotel Marina Tower</td>
<td>Elite Hotel Marina Tower</td>
<td>Eli Lilly and Company</td>
<td>Page 39</td>
</tr>
</tbody>
</table>
HALL OVERVIEW

Stockholmsmässan

Scientific Halls
Symposia Halls
Exhibition

Hellerström Hall
Hall A
Hall B
Jacobsohn Hall
Doniach Hall
Meyer-Schwickerath Hall
Loubatière Hall
Heding Hall
Peltonen-Palotie Hall
Keen Hall
Registration Area
Registration Area
Sterne Hall
Sanger Hall
Hodgkin Hall
Pirart Hall
Schmidt Hall
Bouchardat Hall

EXHIBITION

 Associations' Village

MAIN ENTRANCE

to First Floor

Èlvsjö Station
Programme of Industry Symposia
## INDUSTRY SYMPOSIA

**DIFFERENT PATIENTS, DIFFERENT NEEDS: TOWARDS AN INTEGRATED CARE APPROACH IN DIABETES CARE**

**MONDAY, 14 SEPTEMBER 2015**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 09:00 – 09:10 | Welcome and introduction  
Richard Bergenstal (USA), Lars Rydén (Sweden)                                                |
| 09:10 – 09:20 | Different patients, different needs, different approaches  
Athena Philis-Tsimikas (USA)                                                                         |
| 09:20 – 09:45 | OPTIMISING AND ADVANCING BASAL INSULIN  
The evolution of basal insulin: New insights  
Alice Cheng (Canada)                                                                                 |
| 09:45 – 10:10 | When it’s time to intensify: What are the options?  
Robert Henry (USA)                                                                                   |
| 10:10 – 10:30 | Interactive audience discussion and patient summary  
All                                                                                               |
| 10:30 – 10:50 | Break                                                                                       |
| 10:50 – 11:35 | UNDERSTANDING AND MANAGING RISK IN DIABETES CARE  
Too high or too low: The risks of hyperglycaemia vs hypoglycaemia  
Pratik Choudhary (UK), Silvio Inzucchi (USA)                                                        |
| 11:35 – 12:00 | Getting to the heart of the matter: Understanding cardiovascular risk in diabetes  
Lars Rydén (Sweden)                                                                                 |
| 12:00 – 12:25 | Controlling cholesterol in diabetes  
Bertrand Cariou (France)                                                                              |
| 12:25 – 12:45 | Interactive audience discussion and patient summary  
All                                                                                               |
| 12:45 – 13:45 | Lunch                                                                                       |
| 13:45 – 13:50 | EXPANDING THE HORIZONS OF DIABETES CARE  
Overview of afternoon session  
Richard Bergenstal (USA), Lars Rydén (Sweden)                                                        |
| 13:50 – 14:00 | Different patients, different needs, different approaches  
Partha Kar (UK)                                                                                     |
| 14:00 – 14:25 | Beyond the prescription: Setting, achieving and maintaining target  
Athena Philis-Tsimikas (USA)                                                                         |
| 14:25 – 14:50 | Beyond pharmacotherapy: Technologies that improve how patients interact with their disease  
Steve Edelman (USA)                                                                                  |
| 14:50 – 15:15 | Beyond the clinic: How can we connect with our patients?  
Partha Kar (UK)                                                                                     |
| 15:15 – 15:40 | Patient integrated care: Comprehensive support for better patient outcomes  
Richard Bergenstal (USA), Lars Rydén (Sweden)                                                        |
| 15:40 – 16:00 | Patient summary + closing remarks  
All                                                                                               |

**Organised by: Sanofi Diabetes**
DIFFERENT PATIENTS DIFFERENT NEEDS:
towards an integrated care approach in diabetes

09.00 – 16.00

Optimizing and advancing basal insulin
Understanding and managing risk in diabetes care
Expanding the horizons of diabetes care

Please visit us at booth B06:31, hall B for further information

SANOBI DIABETES  Going beyond together
Evolving Perspectives in Treating Diabetes and Obesity

MORNING SESSION

09:00 – 09:10 Welcome
Host and chair: Bo Ahrén (Sweden)

09:10 – 09:30 Is intensive behavioural therapy enough in obesity management?
Michael Lean (UK)

09:30 – 09:45 Mode of action of liraglutide 3.0 mg in weight management
Niels Vrang (Denmark)

09:45 – 10:00 Focused weight management strategies – update on clinical practice
Nicholas Finer (UK)

10:00 – 10:15 The SCALE phase 3a clinical trial programme – benefits on secondary outcomes
Luc Van Gaal (Belgium)

10:15 – 10:45 Coffee

10:45 – 11:05 Personalising the choice of anti-obesity medication (responder analyses)
Donna Ryan (USA)

11:05 – 11:20 Mechanisms in cardiovascular effects of GLP-1
Mansoor Husain (Canada)

11:20 – 11:45 Managing diabetes in special populations
Melanie Davies (UK)

11:45 – 12:10 Panel discussion

12:10 – 13:10 Lunch

Organised by: Novo Nordisk
Evolving Perspectives in Treating Diabetes and Obesity

Monday, 14 September 2015

Afternoon Session

13:10 – 13:15 Welcome
Host: Bo Ahrén (Sweden), Chair: Tina Vilsbøll (Denmark)

13:15 – 13:35 Hypoglycaemia anno 2015: what we have learned
Simon Heller (UK)

13:35 – 13:55 What is new in insulin treatment?
Tim Heise (Germany) and Christopher Sorli (USA)

13:55 – 14:15 A new choice for diabetes treatment – the dual approach
Stephen Gough (UK)

14:15 – 14:35 The clinical potential of the dual approach
John Buse (USA)

14:35 – 14:50 Panel discussion

14:50 – 15:10 Cardiovascular outcomes trials in diabetes – what have we learned and where are we heading?
Marc Pfeffer (USA)

15:10 – 15:20 Closure
Tina Vilsbøll (Denmark)

Organised by: Novo Nordisk
INDIVIDUALISED PATIENT CARE IN TYPE 2 DIABETES: TRANSLATING SCIENCE TO PRACTICE

MONDAY, 14 SEPTEMBER 2015

10:30 – 11:00 Welcome and introduction
Why and when should we treat Type 2 diabetes?
Chantal Mathieu (Belgium) / Jiten Vora (UK)

11:00 – 11:30 Treatment decisions for our patients: what are the considerations?
Richard Pratley (USA)

11:30 – 11:55 Weight gain in the treatment of Type 2 diabetes: is it inevitable?
John Wilding (UK)

11:55 – 12:20 The kidneys in Type 2 diabetes: challenges and opportunities?
Mark Cooper (Australia)

12:20 – 12:45 Can we delay escalation to insulin therapy?
Tina Vilsbøll (Denmark)

12:45 – 13:00 What steps should we take to stop progression of poor glucose control?
Chantal Mathieu (Belgium) / Jiten Vora (UK)

13:00 – 14:00 Lunch

14:00 – 14:10 Welcome back
Chantal Mathieu (Belgium) / Jiten Vora (UK)

14:10 – 14:40 Safety of novel therapies in Type 2 diabetes: what’s the latest?
Juris Meier (Germany)

14:40 – 15:05 What is the physiological basis for combining therapies?
Jens Holst (Denmark)

15:05 – 15:35 Why not combine earlier?
Jochen Seufert (Germany)

15:35 – 16:00 What can we expect for future management of diabetes?
Melanie Davies (UK)

16:00 – 16:25 How should we make the right treatment choices for our patients?
Chantal Mathieu (Belgium) / Jiten Vora (UK)

16:25 – 16:30 Wrap up and close
Chantal Mathieu (Belgium) / Jiten Vora (UK)

Organised by: AstraZeneca
MONDAY, 14 SEPTEMBER 2015

14:00 – 14:05 Welcome
Co-chairs: Clifford Bailey (UK) and Nikolaus Marx (Germany)

SESSION 1: THE BROKEN HEARTED – CV RISK AND T2D MANAGEMENT
14:05 – 14:25 Tackling CV risk in T2D – time for a change?
Kausik Ray (UK)

14:25 – 14:50 New horizons for managing CV risk with anti-hyperglycaemic agents
Naveed Sattar (UK)

14:50 – 15:10 The evolving landscape of CV outcome trials in T2D
Nikolaus Marx (Germany)

15:10 – 15:25 Q&A
Session 1 faculty

SESSION 2: HEALING HEARTACHE – DOES EMOTIONAL ENGAGEMENT WITH BASAL INSULIN THERAPY IMPROVE OUTCOMES?
15:25 – 15:40 How successful is basal insulin therapy in clinical reality?
Christophe de Block (Belgium)

15:40 – 15:55 Can the empathy of healthcare professionals increase the success of basal insulin treatment in T2D?
Mark Peyrot (USA)

15:55 – 16:00 Q&A
Session 2 faculty

16:00 – 16:05 Closing remarks
Clifford Bailey (UK)

Organised by: Boehringer Ingelheim & Eli Lilly and Company
THE FUTURE OF DIABETES: OPPORTUNITIES AND CHALLENGES

MONDAY, 14 SEPTEMBER 2015

Chair: Anthony Barnett (UK)

Guest speaker: Sir Michael Hirst (UK)

Faculty members: Kamlesh Khunti (UK)
Mark Cooper (Australia)
Focke Ziemssen (Germany)
Matthias Blüher (Germany)

13:30 – 14:30 PART 1: The vision – opportunities and challenges
14:30 – 14:50 Refreshment break

14:50 – 17:00 PART 2: The reality - opportunities and challenges
14:50 – 15:50 Will optimised diabetes care be accessible in the future?
15:50 – 17:00 Will we be able to prevent the future?

Organised by: Novartis Pharmaceuticals
THE FUTURE OF DIABETES
Opportunities & challenges

A Novartis-sponsored symposium on the occasion of the 51st Annual Meeting of the European Association for the Study of Diabetes

14 September 2015
13:30–17:00
Jacobsohn Hall,
Stockholmsmässan,
Stockholm, Sweden

Faculty

Anthony Barnett (Chair), UK
Sir Michael Hirst, UK
Kamlesh Khunti, UK
Mark Cooper, Australia
Focke Ziemssen, Germany
Matthias Blüher, Germany

Agenda

13:30–14:30       PART 1: The vision - opportunities and challenges
14:30–14:50       Refreshment break
14:50–17:00       PART 2: The reality - opportunities and challenges
14:50–15:50       Will optimised diabetes care be accessible in the future?
15:50–17:00       Will we be able to prevent the future?
DEXCOM CONTINUOUS GLUCOSE MONITORING IN 2015 – CLINICAL PRACTICE, TECHNOLOGY INNOVATIONS AND MARKET ACCESS

MONDAY, 14 SEPTEMBER 2015

10:00 – 12:30
Meyer-Schwickerath Hall

Moderator: Peter Adolfsson (Sweden)

10:00 – 10:50 Using Dexcom CGM in Clinical Practice – Education and Medical Management
Peter Adolfsson (Sweden)

10:50 – 11:40 Current and Future Dexcom CGM Technology Innovations
Jake Leach (USA)

11:40 – 12:30 Continuous Glucose Monitoring – Cost Modeling and Reimbursement
Claudia Graham (USA)

Organised by: DexCom
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 – 10:10</td>
<td>Welcome and Opening</td>
<td>Julia Brosnan (USA)</td>
</tr>
<tr>
<td>10:10 – 10:40</td>
<td>A fine-tuned classification of diabetes – steps towards individualized medicine</td>
<td>Leif Groop (Sweden)</td>
</tr>
<tr>
<td>10:40 – 11:20</td>
<td>Rare and Frequent DNA Variation and Precision Diabetic Medicine</td>
<td>Philippe Froguel (France)</td>
</tr>
<tr>
<td>11:20 – 11:50</td>
<td>Building a target hypothesis: genetic associations are only the start</td>
<td>Daniel Ziemek (Germany)</td>
</tr>
<tr>
<td>11:50 – 12:30</td>
<td>Diamonds in the Dirt – using human genetics to Define Biology and Guide translation in type 2 Diabetes</td>
<td>Mark McCarthy (UK)</td>
</tr>
</tbody>
</table>

Organised by: Pfizer
SAROGLITAZAR – A BREAKTHROUGH DISCOVERY IN THE MANAGEMENT OF METABOLIC DISORDERS

MONDAY, 14 SEPTEMBER 2015

14:30 – 17:00
Rahbar Hall A

Chairs
Banshi Saboo (India), S. K. Sharma (India)

14:30 – 14:50
Diabetic dyslipidemia & its management: Review of current therapeutic options
Charles Burant (USA)

14:50 – 15:10
PPAR agonism: Role in metabolic disorders
Walter Wahli (Switzerland)

15:10 – 15:30
Saroglitazar: Concept to clinic
Shashank R. Joshi (India)

15:30 – 15:50
Saroglitazar: An endocrinologist’s perspective
Anil Bhansali (India)

15:50 – 16:10
Saroglitazar: A cardiologist’s perspective
Saumitra Ray (India)

16:10 – 16:30
Saroglitazar: NASH perspective
Sujoy Ghosh (India)

16:30 – 17:00
Panel discussion

Organised by: Zydus Cadila
LESSONS LEARNED FROM THE TECOS CV SAFETY TRIAL AND THE EVOLVING ROLE OF DPP-4 INHIBITORS IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES

MONDAY, 14 SEPTEMBER 2015

14:30 – 14:35  Chair Welcome and Opening Remarks
Co-Chairs: Rury Holman (UK), Michel Komajda (France)

14:35 – 15:05  Are we Treating Patients Based on the Evidence?
Previous Cardiovascular Trials: Michel Komajda (France)
DPP-4 CV Safety Trials: Michael Nauck, (Germany)

15:05 – 15:20  Audience Vote and Discussion led by Chairmen

15:20 – 15:40  DPP-4 Inhibitors: What is the Latest Science?
Carolyn Deacon (Denmark)

15:40 – 15:50  Q&A

15:50 – 16:20  Lessons Learned from the TECOS CV Safety Trial: The Role of Sitagliptin in the Treatment of Cardiovascular Patients with Type 2 Diabetes
Rury Holman (UK)

16:20 – 16:30  Q&A

16:30 – 16:55  Specialty Dialogue: Treatment of Patients with Type 2 Diabetes from an Endocrinology, Nephrology and Cardiology View
Faculty

16:55 – 17:00  Final Comments and Summary
Chairmen: Rury Holman (UK), Michel Komajda (France)

Organised by:  Merck Sharp & Dohme
DIABETIC DYSLIPIDEMIA, CARDIOVASCULAR DISEASE AND PCSK9 INHIBITION WITH EVOLOCUMAB: 4 KEY QUESTIONS

MONDAY, 14 SEPTEMBER 2015
14:30 – 17:00
Meyer-Schwickerath Hall

14:30 – 14:35 Welcome and introduction
Marja-Riitta Taskinen (Finland)
Handrean Soran (UK)

14:35 – 15:05 Targeting dyslipidemia in diabetes, is it important?
Neil Poulter (UK)

15:05 – 15:35 Patients who cannot tolerate a maximum dose of statins, what should we do?
Ulrich Laufs (Germany)

15:35 – 16:05 What is PCSK9 and why should you be interested in it?
John Chapman (France)

16:05 – 16:45 Debate: Is LDL-C reduction more important than glucose lowering in diabetes?
For: Kausik Ray (UK)
Against: Naveed Sattar (UK)

16:45 – 17:00 Panel questions and closing remarks
Marja-Riitta Taskinen (Finland)
Handrean Soran (UK)

Organised by: Amgen
Diabetic dyslipidemia, cardiovascular disease and PCSK9 inhibition with evolocumab: 4 key questions

Monday 14 September 2015, 14.30–17.00
Meyer-Schwickerath Hall, Stockholmsmässan, Stockholm, Sweden

PROGRAMME

Welcome and introduction
Marja-Riitta Taskinen, Finland and Handrean Soran, UK

Targeting dyslipidemia in diabetes, is it important?
Neil Poulter, UK

Patients who cannot tolerate a maximum dose of statins, what should we do now?
Ulrich Laufs, Germany

What is PCSK9 and why should you be interested in it?
John Chapman, France

Debate: Is LDL-C reduction more important than glucose lowering in diabetes?
For: Kausik Ray, UK  Against: Naveed Sattar, UK

Panel questions and closing remarks
Marja-Riitta Taskinen, Finland and Handrean Soran, UK
MONDAY, 14 SEPTEMBER 2015  
14:30 – 17:00  
Rahbar Hall B

14:00 – 14:30   Registration

14:30 – 14:35   Welcome, Faculty Disclosures and Program Objectives

14:35 – 14:40   Pre-test Using Audience Response System

14:40 – 15:00   Current Perspectives on Insulin Dynamics in the Subcutaneous Space  
Prof. Lutz Heinemann (Germany)

15:00 – 15:30   The Science of Infusion Sets: Gaps in Clinical Evidence  
Dr. Bruce A. Buckingham (USA)

15:30 – 15:50   Paediatric Clinical Case  
Prof. Thomas Danne (Germany)

15:50 – 16:10   New Insulin Infusion Set Technology  
Dr. Laurence J. Hirsch (USA)

16:10 – 16:20   Toward the Artificial Pancreas: Clinical Perspectives on Opportunities and Gaps  
Prof. J. Hans De Vries (The Netherlands)

Dr. Aaron Kowalski (USA)

16:30 – 16:45   Demonstrations

16:45 – 16:50   Questions & Answers

16:50 – 16:55   Post-test Using Audience Response System

16:55 – 17:00   Closing Remarks

Organised by:  Becton Dickinson & Company Inc.
OPTIMIZING INSULIN PUMP THERAPY

Infusion Set Failures and Silent Occlusions

MONDAY, 14 SEPTEMBER 2015
14:30–17:00
Rahbar Hall B
Stockholmsmässan
Stockholm, Sweden

EDUCATIONAL OBJECTIVES
After participating in the symposium, the learner will be able to:

• Recognize knowledge gaps and technical issues associated with the use of insulin infusion sets, including flow interruptions with infusion sets
• Identify strategies to improve patient and healthcare professional knowledge gaps around insulin infusion sets
• Review potential benefits of new infusion set technology in clinical care

AGENDA
14:00–14:30
Registration and Light Refreshments
14:30–14:35
Welcome, Faculty Disclosures, and Program Objectives
14:35–14:40
Pre-test Using Audience Response System
14:40–15:00
Current Perspectives on Insulin Dynamics in the Subcutaneous Space
Lutz Heinemann, PhD
15:00–15:30
The Science of Infusion Sets: Gaps in Clinical Evidence
Bruce A. Buckingham, MD
15:30–15:50
Paediatric Clinical Case
Thomas Danne, MD
15:50–16:10
New Insulin Infusion Set Technology
Laurence J. Hirsch, MD
16:10–16:20
Toward the Artificial Pancreas: Clinical Perspectives on Opportunities and Gaps
J. Hans De Vries, MD, PhD
16:20–16:30
New Research: What the Future Holds
Aaron Kowalski, PhD
16:30–16:45
Demonstrations
16:45–16:50
Questions & Answers
16:50–16:55
Post-test Using Audience Response System
16:55–17:00
Closing Remarks

Register at
www.bdsympo2015.com

For more information, please email
maryjo.holden@athenaedgroup.com

Provided by
Athena Education Group, LLC

BD, BD logo and all other trademarks are property of Becton, Dickinson and Company © 2015 BD
SHOULD TYPE 2 DIABETES (T2D) MANAGEMENT BE MORE OF A PRIORITY IN POST-ACUTE CORONARY SYNDROME (ACS) PATIENTS?

MONDAY, 14 SEPTEMBER 2015  14:30 – 17:00
Kimmelstiel Hall

Chair: Ele Ferrannini (Italy)

14:30 – 14:45 Welcome
Ele Ferrannini (Italy)

14:45 – 15:10 The ACS patient journey: where does T2D fit in?
Jean-Claude Tardif (Canada)

15:10 – 15:50 Perspectives of diabetes and cardiovascular-risk management in post-ACS T2D patients
- Cardiologist’s perspective
  Stephen Nicholls (Australia)
- Diabetologist’s perspective
  Jørgen Rungby (Denmark)

15:50 – 16:30 What do we know about the safety of oral anti-diabetics in post-ACS T2D patients? Exploring evidence from recent outcomes studies
Faiez Zannad (France)

16:30 – 16:55 Debating the optimal management of post-ACS T2D patients
All speakers, facilitated by Ele Ferrannini

16:55 – 17:00 Conclusions and close
Ele Ferrannini (Italy)

Organised by: Takeda
Should **type 2 diabetes (T2D)** management be more of a priority in **post-acute coronary syndrome (ACS)** patients?

Putting the spotlight on T2D management in post-ACS patients

**Chair: Professor Ele Ferrannini**

Takeda-sponsored symposium
Kimmelstiel Hall,
Monday 14 September 2015; 14:30–17:00

On the occasion of the 51st Annual Meeting of the European Association for the Study of Diabetes, Stockholm, Sweden, 14 – 18 September 2015
MONDAY, 14 SEPTEMBER 2015

14:30 – 14:40
Introduction

14:40 – 15:05
Surfing safely in the diabetes app tsunami
Ashleigh Walker (Canada)

15:05 – 15:30
The benefits mobile health solutions like the Accu-Chek® Connect system can bring to Personalized Diabetes Management
Fabio Broglio (Italy)

15:30 – 15:55
Personalized Diabetes Management today and tomorrow – options for better diabetes therapy
Matthias Axel Schweitzer (Germany)

15:55 – 16:20
First results of the Accu-Chek® Insight EU Study
Julia Mader (Austria)

16:20 – 16:45
CGM – Developments, indications, performance
Peter Adolfsson (Sweden)

16:45 – 17:00
Discussion and closing

Organised by: Roche Diabetes Care
New Accu-Chek® solutions for you

The Accu-Chek® Connect diabetes management system
Better connected for better decisions

The Accu-Chek® Insight diabetes therapy system
Designed with your patients’ lives in mind

Visit us in Hall B at stand 10.31 and find out more

Experience what’s possible.

For more information about Accu-Chek, visit www.accu-chek.com
ACCU-CHEK, ACCU-CHEK AVIVA CONNECT, ACCU-CHEK AVIVA INSIGHT,
ACCU-CHEK CONNECT and ACCU-CHEK INSIGHT are trademarks of Roche.
© 2015 Roche Diabetes Care

www.accu-chek.com
Roche Diabetes Care GmbH
Sandhofer Str. 116
D-68305 Mannheim
## SHOULD SGLT2 INHIBITORS BE AN INTEGRAL PART OF A PERSONALIZED TREATMENT PLAN FOR TYPE 2 DIABETES?

**MONDAY, 14 SEPTEMBER 2015**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 – 14:40</td>
<td>Introduction and Welcome</td>
<td>Guntram Schernthaner (Austria)</td>
</tr>
<tr>
<td>14:40 – 15:00</td>
<td>Updates on the Clinical and Physiologic Effects of SGLT2 Inhibition:</td>
<td>Guntram Schernthaner (Austria)</td>
</tr>
<tr>
<td></td>
<td>What Have We Learned?</td>
<td></td>
</tr>
<tr>
<td>15:00 – 15:30</td>
<td>Expanding Treatment Options for Glycemic Reduction in Patients with</td>
<td>Francisco Javier Ampudia-Blasco (Spain)</td>
</tr>
<tr>
<td></td>
<td>T2DM: Role of SGLT2 Inhibitors</td>
<td></td>
</tr>
<tr>
<td>15:30 – 15:55</td>
<td>Non-glycemic Effects of SGLT2 Inhibitors: How Novel Antihyperglycemic</td>
<td>Ronan Roussel (France)</td>
</tr>
<tr>
<td></td>
<td>Therapy May Improve Patient Outcomes</td>
<td></td>
</tr>
<tr>
<td>15:55 – 16:40</td>
<td>Putting It All Together: Practical Considerations for Using SGLT2</td>
<td>John P. H. Wilding (UK)</td>
</tr>
<tr>
<td></td>
<td>Inhibitors in the Management of Patients with T2DM</td>
<td></td>
</tr>
<tr>
<td>16:40 – 16:58</td>
<td>Q&amp;A Session</td>
<td>Faculty Panel</td>
</tr>
<tr>
<td>16:58 – 17:00</td>
<td>Conclusions</td>
<td>John P. H. Wilding (UK)</td>
</tr>
</tbody>
</table>

**Organised by:** Medscape Education

supported by an independent educational grant from Janssen
MONDAY, 14 SEPTEMBER 2015

14:35 – 15:05 Clinical experience with FreeStyle Libre
Stig Attvall (Sweden)

15:05– 15:35 Ambulatory Glucose Profile (AGP) through the diabetes care continuum
Dr. med. Oliver Schubert (Germany)

15:35 – 16:05 The Impact of AGP and FreeStyle Libre on the Patient – Clinician Dialogue in T1 Diabetes
Stephen Dixon and Dr. Pratik Choudhary (UK)

16:05 – 16:35 The Impact of AGP and FreeStyle Libre on the Patient – Clinician Dialogue in T2 Diabetes
Dr. med. Oliver Schubert (Germany)

16:40 – 17:00 Panel Discussion
Professor Jan Bolinder and all Presenters

Organised by: Abbott
WHAT IS THE OPTIMIZED TREATMENT FOR T2DM PATIENTS?

MONDAY, 14 SEPTEMBER 2015  17:00 – 18:00
Schmidt Hall

17:00 – 17:10  Welcome Address of Chairman
Prof. Moon-Kyu Lee (Korea)

17:10 – 17:30  Gemigliptin: The Optimized DPP-4 inhibitor for T2DM Patients
Prof. Soo Lim (Korea)

17:30 – 17:50  The Optimal Management in T2DM Patients with Renal Impairment
Prof. Eun-Jung Rhee (Korea)

17:50 – 18:00  Q&A and Closing

Organised by:  LG Life Sciences
What is the Optimized Treatment for T2DM Patients?

Date | Mon. 14th Sep. 2015, 17:00~18:00
Place | Schmidt Hall

17:00 ~ 17:10
Welcome Address of Chairman
by Prof. Moon-Kyu Lee, Sungkyunkwan University School of Medicine, Korea

17:10 ~ 17:30
Gemigliptin: The Optimized DPP-4 inhibitor for T2DM Patients.
by Prof. Soo Lim, Seoul National University College of Medicine, Korea

17:30 ~ 17:50
The Optimal Management in T2DM Patients with Renal Impairment
by Prof. Eun-Jung Rhee, Sungkyunkwan University School of Medicine, Korea

17:50 ~ 18:00
QnA and Closing
THE METABOLIC CHAOS OF LIPODYSTROPHY – FINDING THE ORDER WITHIN

MONDAY, 14 SEPTEMBER 2015  17:00 – 18:00
Hodgkin Hall

Keynote speaker: Prof. Abhimanyu Garg (USA)

17:00 – 17:05  Welcome and introduction
17:05 – 17:45  Keynote speech
Prof. Abhimanyu Garg (USA)
17:45 – 18:00  Questions and Answers

Organised by: Aegerion
## MONDAY, 14 SEPTEMBER 2015

17:00 – 17:05  Welcome & Objectives

17:05 – 17:20  Cardiovascular Risk in Diabetes Patients: Just About Lipid Modification?  
Peter J. Grant (United Kingdom)

17:20 – 17:35  Dyslipidemia and Atherogenicity in T2DM: Looking Beyond the Obvious  
Alberto Zambon (Italy)

17:35 – 17:50  What is the Role of CETP in Lipid Metabolism?  
José María Mostaza Prieto (Spain)

17:50 – 18:00  Expert Panel

---

**Organised by:** Eli Lilly and Company
SAVE THE DATE
INDUSTRY PROGRAMME
on the occasion of the
52\textsuperscript{nd} Annual Meeting
of the European Association
for the Study of Diabetes
Munich
12 – 16 September 2016

12 September 2016
Industry Symposia & Industry Mini Symposia

13 – 15 September 2016
Industry Exhibition

15 September 2015
Industry Evening Symposia

www.easd-industry.com
GLP-1 RECEPTOR AGONISTS:
LIRAGLUTIDE 3.0 MG IN WEIGHT MANAGEMENT

THURSDAY, 17 SEPTEMBER 2015
19:00 – 20:30
Loubatière Hall

19:00 – 19:05  Welcome and introduction
                Joanna Uddén Hemmingsson (Sweden)

19:05 – 19:20  The role of GLP-1 in weight management: targeting central nervous
                system appetite regulation
                Darleen Sandoval (USA)

19:20 – 19:35  Optimising the dose for weight management: phase 2 results
                Nick Finer (UK)

19:35 – 20:00  SCALE Obesity and Prediabetes & SCALE Maintenance: key results
                Carel Le Roux (Ireland)

20:00 – 20:15  SCALE Diabetes: key results
                Tina Vilsbøll (Denmark)

20:15 – 20:30  Panel discussion
                All faculty

Organised by:  Novo Nordisk
## EMPA-REG OUTCOME®: IMPLICATIONS FOR MANAGEMENT OF PATIENTS WITH TYPE 2 DIABETES

**THURSDAY, 17 SEPTEMBER 2015**  
19:00 – 20:30  
Meyer-Schwickerath Hall

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>19:00 – 19:05</td>
<td>Welcome and introduction</td>
<td>Lars Rydén (Sweden)</td>
</tr>
<tr>
<td>19:05 – 19:40</td>
<td>Exploring the results of EMPA-REG OUTCOME®</td>
<td>Bernard Zinman (Canada)</td>
</tr>
<tr>
<td>19:40 – 20:20</td>
<td>Treatment of Type 2 Diabetes and cardiovascular risk in the context of EMPA-REG OUTCOME®</td>
<td>Lars Rydén (Sweden)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sanjay Kaul (USA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lawrence Leiter (Canada)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Naveed Sattar (UK)</td>
</tr>
<tr>
<td>20:20 – 20:30</td>
<td>Conclusion, summary and close</td>
<td>Lars Rydén (Sweden)</td>
</tr>
</tbody>
</table>

**Organised by:** Boehringer Ingelheim & Eli Lilly and Company
JARDIANCE, an SGLT2 inhibitor for adults with type 2 diabetes, provides:

- Significant HbA1c reduction with the additional benefit of weight loss2,5,†
- Efficacy when added to a range of background treatments, including insulin3,5
- Convenient once-daily oral dosing

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.

Jardiance (empagliflozin)

SYNJARDY

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.

Jardiance (empagliflozin)

SYNJARDY

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.

Jardiance (empagliflozin)

SYNJARDY

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.

Jardiance (empagliflozin)

SYNJARDY

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.

Jardiance (empagliflozin)

SYNJARDY

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.

Jardiance (empagliflozin)

SYNJARDY

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.

Jardiance (empagliflozin)

SYNJARDY

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.

Jardiance (empagliflozin)

SYNJARDY

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.

Jardiance (empagliflozin)

SYNJARDY

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.

Jardiance (empagliflozin)

SYNJARDY

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.

Jardiance (empagliflozin)

SYNJARDY

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.

Jardiance (empagliflozin)

SYNJARDY

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.

Jardiance (empagliflozin)

SYNJARDY

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.

Jardiance (empagliflozin)

SYNJARDY

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.

Jardiance (empagliflozin)

SYNJARDY

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.

Jardiance (empagliflozin)

SYNJARDY

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.

Jardiance (empagliflozin)

SYNJARDY

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.

Jardiance (empagliflozin)

SYNJARDY

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.

Jardiance (empagliflozin)

SYNJARDY

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.

Jardiance (empagliflozin)

SYNJARDY

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.

Jardiance (empagliflozin)

SYNJARDY

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.

Jardiance (empagliflozin)

SYNJARDY

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

- The efficacy of both empagliflozin and metformin in 1 pill†,†
- Flexible dosing options to individualise treatment6
- The convenience of a single-pill combination for your patients

Now those are benefits your patients could appreciate.
THE TECOS CV SAFETY TRIAL AND THE LESSONS LEARNED FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE

THURSDAY, 17 SEPTEMBER 2015

Co-Chairs: Niko Marx (Germany)
Juris Meier (Germany)

19:00 – 19:05 Welcome
Niko Marx (Germany) and Juris Meier (Germany)

19:05 – 19:20 Continuing our Understanding of the Role DPP-4 Inhibitors Play in the Cardiovascular Patient with Type 2 Diabetes
Richard Gilbert (Canada)

19:20 – 19:30 Q and A

19:30 – 19:55 TECOS CV SAFETY TRIAL: New Data from the CV Safety Trial for Sitagliptin
Rury Holman (UK)

19:55 – 20:05 Q and A

20:05 – 20:25 Faculty Specialty Dialogue: Lessons Learned for the Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease
All faculty

20:25 – 20:30 Closing Comments
Niko Marx (Germany) and Juris Meier (Germany)

Organised by: Merck Sharp & Dohme
# The Patient in Mind: New Perspectives on Injectable Therapy for Type 2 Diabetes

**Thursday, 17 September 2015**

**19:00 – 20:30**

*Elite Hotel Marina Tower*

**Chair:** Michael Nauck (Germany)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>19:00 – 19:05</td>
<td>Introduction/Opening</td>
<td>Michael Nauck (Germany)</td>
</tr>
<tr>
<td>19:05 – 19:25</td>
<td>Understanding the T2DM patient transition to injectable therapy</td>
<td>Melanie Davies (UK)</td>
</tr>
<tr>
<td>19:45 – 20:10</td>
<td>Can weekly GLP-1 RAs influence the current perspective of injectable therapies? A commentary on the latest data</td>
<td>Michael Nauck (Germany)</td>
</tr>
<tr>
<td>20:10 – 20:30</td>
<td>Panel discussion + Wrap up</td>
<td>Michael Nauck (Germany)</td>
</tr>
</tbody>
</table>

**Please note** this meeting is by registration only. Please contact Lilly staff for further details.

**Organised by:** Eli Lilly and Company
FIND YOUR PERFECT PLACE TO STAY IN MUNICH!

http://hotels2016.easd-industry.com/

Username: hotels2016
Password: Munich*16

The hotel capacities are limited and it is recommended to arrange your booking early.

FOR FURTHER DETAILS, PLEASE CONTACT
INTERPLAN
Congress, Meeting & Event Management AG
Landsberger Str. 155
80687 Munich, Germany
Phone:  +49 89 - 54 82 34-9055
Email:  hotels2016@interplan.de
Due to safety reasons, the entrance to the conference site during the industry symposia on the occasion of the 51st EASD Annual Meeting will be strictly controlled.

This means that each regular attendee of the symposia day has to be identified as authorised by wearing a badge.

Our security staff will accept the following types of badges or name labels only:

- Regular delegate badge
- Regular exhibitor badge
- Special name tags, provided by the company itself, showing the status of the person wearing: “Invited by …, Guest of …, Technician of…”

<table>
<thead>
<tr>
<th>Type of Delegate</th>
<th>Type of Badge</th>
<th>Access to Industry Symposia 14.09.15</th>
<th>Access to the Scientific Sessions 15.– 18.09.15</th>
<th>Access to Industry Evening Symposia 17.09.15</th>
<th>Access to the Industry Exhibition 15.– 17.09.15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker / Delegate registered for the Scientific Programme of the EASD Annual Meeting</td>
<td>Congress Badge</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Speaker / Delegate registered as an exhibitor for the Industry Exhibition of the EASD Annual Meeting</td>
<td>Exhibitor Badge</td>
<td>✔</td>
<td>✗</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Company Speaker / Delegate not registered for the EASD Annual Meeting</td>
<td>Own Company created Badge</td>
<td>✔</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
</tr>
</tbody>
</table>
ABASAGLAR 100 units/mL solution for injection (insulin glargine)
Cartridge, pre-filled pen (KwikPen™)

This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions.

ATC code: A10AE04
Drugs used in diabetes. Insulins and analogues for injection, long-acting.

Indications: Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.

Contraindications: Hypersensitivity to the active substance or to any of the excipients.

Warnings: ABASAGLAR is not the insulin of choice for the treatment of diabetic ketoacidosis. Instead, regular insulin administered intravenously is recommended in such cases. In case of insufficient glucose control or a tendency to hyperglycaemic or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.

Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type (regular, NPH, lente, long acting, etc.), origin (animal, human, human insulin analogue) and/or method of manufacture may result in the need for a change in dose.

Insulin administration may cause insulin antibodies to form. In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia.

Date of revision of the text: 17 February 2015

For further information and prices see www.fass.se

Rx, not F

This text is based on the Swedish prescribing information. Please contact your local Lilly representative for information relevant to your country.

Eli Lilly Sweden AB, Box 721, 169 27 Solna. 08-737 88 00. www.lilly.se.
Join us at this state-of-the-art symposium and be one of the first to discuss the results of the EMPA-REG OUTCOME™ trial with leading experts.